Shionogi buys rare disease startup IntraBio for $2B

Shionogi has acquired Texas-based rare disease startup IntraBio for $2 billion, adding a treatment for inherited neurological conditions to its growing specialty business. The deal, announced today, marks Shionogi’s largest acquisition in recent years and its latest move into rare diseases.

IntraBio’s lead asset is approved for two indications, including a lysosomal storage disorder. The company also has a pipeline of preclinical candidates targeting neurodegenerative diseases. Shionogi has been expanding its rare-disease efforts, and this acquisition may further bolster that strategy.

The $2 billion price tag suggests confidence in the startup’s commercial potential, though details about revenue or infrastructure remain undisclosed. The deal aligns with a pattern of pharmaceutical companies acquiring startups with marketed rare-disease treatments, even as broader biotech valuations fluctuate. While some startups, like AI coding company Cognition, have rapidly scaled to near-billion-dollar revenues, IntraBio’s profile—with a single approved drug—represents a more traditional biotech exit. It remains to be seen whether Shionogi will retain IntraBio’s team or integrate its operations. The company has not shared plans for the transition.

Sources: biopharmadive.com